Sera Prognostics, Inc. (SERA)
- Previous Close
2.5200 - Open
2.5100 - Bid 2.3600 x 100
- Ask 2.4400 x 100
- Day's Range
2.3600 - 2.6400 - 52 Week Range
2.3600 - 10.2300 - Volume
223,484 - Avg. Volume
115,896 - Market Cap (intraday)
90.406M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9900 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
www.sera.comRecent News: SERA
View More
Performance Overview: SERA
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SERA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SERA
View MoreValuation Measures
Market Cap
90.41M
Enterprise Value
45.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.03k
Price/Book (mrq)
1.89
Enterprise Value/Revenue
584.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.26%
Return on Equity (ttm)
-55.78%
Revenue (ttm)
77k
Net Income Avi to Common (ttm)
-32.9M
Diluted EPS (ttm)
-0.9900
Balance Sheet and Cash Flow
Total Cash (mrq)
46.24M
Total Debt/Equity (mrq)
1.76%
Levered Free Cash Flow (ttm)
-4.76M